Compass Ion Advisors, LLC Cullinan Oncology, Inc. Transaction History
Compass Ion Advisors, LLC
- $958 Million
- Q3 2025
A detailed history of Compass Ion Advisors, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Compass Ion Advisors, LLC holds 13,904 shares of CGEM stock, worth $119,018. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,904Holding current value
$119,018% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CGEM
# of Institutions
154Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$65.5 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.2 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$37.7 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$33 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.4 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $390M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...